The Gain in Quality-Adjusted Life Months by Switching to Esomeprazole in Those With Continued Reflux Symptoms in Primary Care: EncomPASS—A Cluster-Randomized Trial

@article{Moayyedi2010TheGI,
  title={The Gain in Quality-Adjusted Life Months by Switching to Esomeprazole in Those With Continued Reflux Symptoms in Primary Care: EncomPASS—A Cluster-Randomized Trial},
  author={Paul M Moayyedi and David Armstrong and Richard H. Hunt and Yao Hui Lei and Margaret Bukoski and Robert J. White},
  journal={The American Journal of Gastroenterology},
  year={2010},
  volume={105},
  pages={2341-2346}
}
OBJECTIVES:Proton pump inhibitors (PPIs) are effective in gastroesophageal reflux disease (GERD), but their cost effectiveness is unknown. This is usually determined by cost/quality-adjusted life year (QALY) gained, but whether PPI therapy improves QALYs has not been assessed in a randomized trial. The PPI acid suppression symptom (PASS) test is a five-item questionnaire that identifies patients with persistent acid-related symptoms. We evaluated whether a PASS test-based management strategy of… CONTINUE READING
14 Citations
23 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Who pays the piper ?

  • P Moayyedi
  • J Clin Gastroenterol
  • 2007

Similar Papers

Loading similar papers…